Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:alternativeName |
STH104
|
| gptkbp:CASNumber |
2220012-22-6
|
| gptkbp:developer |
Satori Pharmaceuticals
|
| gptkbp:drugClass |
benzodiazepine
antidepressant |
| gptkbp:hasMolecularFormula |
C20H19FN2O3
|
| gptkbp:hasSMILES |
COC1=CC=C(C=C1)C(=O)C(N(C)C2=CC=C(C=C2)F)=O
|
| gptkbp:hasTherapeuticUse |
treatment of depression
treatment of anxiety |
| https://www.w3.org/2000/01/rdf-schema#label |
STH-104
|
| gptkbp:IUPACName |
N-(4-fluorophenyl)-2-(4-methoxyphenyl)-N-methyl-2-oxoacetamide
|
| gptkbp:mechanismOfAction |
positive allosteric modulator of GABAA receptor
|
| gptkbp:molecularWeight |
354.38 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL4297592
137517209 |
| gptkbp:bfsParent |
gptkb:Wisconsin_Highway_104
|
| gptkbp:bfsLayer |
7
|